Upgrade your membership to see all of the expert analysis we have published on LLY now!
Hovering Near "Max Buy" Level With Volume Totals Cooling - Friday, July 22, 2022
Eli Lilly & Co (LLY +$1.83 or +0.56% to $328.75) posted a 2nd consecutive quiet gain today. It has been hovering near its "max buy" level and all-time high with light volume totals in recent weeks. Its 50-day moving average (DMA) line ($311) defines near-term support to watch.
LLY was highlighted in yellow with pivot point cited based on its 4/07/22 high plus 10 cents in the 5/16/22 mid-day report (read here). This giant Medical - Diversified firm showed impressive resilience and strength after slumping below its 50 DMA line since last covered in greater detail on 7/08/22 with an annotated graph under the headline, "Lilly Quietly Wedged to a New All-Time High This Week".
Keep in mind that it is due to report Jun '22 quarterly results on 8/04/22. Volume and volatility often increase near earnings news. Fundamentals have been strong. LLY has a 93 Earnings Per Share Rating, well above the 80+ minimum for buy candidates. It reported Mar '22 quarterly earnings +63% on +15% sales revenues versus the year ago period. Three of the past 4 quarterly comparisons were above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) improved steadily since a downturn in FY '14.
The number of top-rated funds owning its shares rose from 3,055 in Dec '20 to 3,738 in Jun '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.8 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness Rating of A and a Sponsorship Rating of B. There are 950.2 million shares outstanding, making it an unlikely sprinter, while it is also well-recognized already by the institutional crowd.
Lilly Quietly Wedged to a New All-Time High This Week - Friday, July 8, 2022
Eli Lilly & Co (LLY +$2.52 or +0.77% to $330.47) posted a gain with light volume and its color code was changed to green after closing above its "max buy" level. On pullbacks, its 50-day moving average (DMA) line ($303) defines near-term support above prior lows.
LLY was highlighted in yellow with pivot point cited based on its 4/07/22 high plus 10 cents in the 5/16/22 mid-day report (read here). This giant Medical - Diversified firm showed impressive resilience and strength after slumping below its 50 DMA line since last covered in greater detail on 6/06/22 with an annotated graph under the headline, "Encountering Distributional Pressure After Reaching New Highs".
Fundamentals remain strong. LLY has a 93 Earnings Per Share Rating, well above the 80+ minimum for buy candidates. It reported Mar '22 quarterly earnings +63% on +15% sales revenues versus the year ago period. Three of the past 4 quarterly comparisons were above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) improved steadily since a downturn in FY '14.
The number of top-rated funds owning its shares rose from 3,055 in Dec '20 to 3,695 in Jun '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.6 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness Rating of A and a Sponsorship Rating of B. There are 950.2 million shares outstanding, making it an unlikely sprinter, while it is also well-recognized already by the institutional crowd.
Encountering Distributional Pressure After Reaching New Highs - Monday, June 6, 2022
Eli Lilly & Co (LLY +$1.71 or +0.57% to $303.36) is consolidating above its 50-day moving average (DMA) line ($297) which defines important near-term support to watch. It has encountered distributional pressure with volume-driven losses. Although it recently wedged above the pivot point cited based on its 4/07/22 high plus 10 cents, the gains above the pivot point lacked the minimum +40% above average volume necessary to clinch a convincing technical buy signal. Confirming gains for new highs with at least +40% above average volume would be a reassuring sign of fresh institutional buying demand.
LLY was highlighted in yellow with pivot point cited based on its 4/07/22 high plus 10 cents in the 5/16/22 mid-day report (read here). This giant Medical - Diversified firm was covered in greater detail that evening with an annotated graph under the headline, "Eli Lilly & Co Challenges All-Time High".
Fundamentals remain strong. LLY has a 92 Earnings Per Share Rating, well above the 80+ minimum for buy candidates. It reported Mar '22 quarterly earnings +63% on +15% sales revenues versus the year ago period. Three of the past 4 quarterly comparisons were above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) improved steadily since a downturn in FY '14.
The number of top-rated funds owning its shares rose from 3,055 in Dec '20 to 3,538 in Mar '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.0 is an unbiased indication its shares have been neutral concerning accumulation/distribution over the past 50 days. It has a Timeliness Rating of A and a Sponsorship Rating of B. There are 950.2 million shares outstanding, making it an unlikely sprinter, while it is also well-recognized already by the institutional crowd.
Eli Lilly & Co Challenges All-Time High - Monday, May 16, 2022
Eli Lilly & Co (LLY +$7.75 or +2.66% to $299.38) was highlighted in yellow with pivot point cited based on its 4/07/22 high plus 10 cents in the earlier mid-day report (read here). It challenged its 52-week high with its early gain but finished near the middle of the session's trading range. LLY found support near prior highs and its 50-day moving average (DMA) line ($289) during a 6-week consolidation. Subsequent gains and a close above the pivot point backed by at least +40% above average volume may trigger a technical buy signal. Members have been repeatedly cautioned - "New buying efforts may only be considered after a solid follow-through day confirms a new market uptrend (M criteria) under the fact-based investment system. Follow this closely in the daily market commentaries."
LLY has a 95 Earnings Per Share Rating, well above the 80+ minimum for buy candidates. It reported Mar '22 quarterly earnings +63% on +15% sales revenues versus the year ago period. Three of the past 4 quarterly comparisons were above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) improved steadily since a downturn in FY '14.
LLY has a 95 Earnings Per Share Rating, well above the 80+ minimum for buy candidates. It reported Mar '22 quarterly earnings +63% on +15% sales revenues versus the year ago period. Three of the past 4 quarterly comparisons were above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) improved steadily since a downturn in FY '14.
This giant Medical - Diversified firm was last covered in greater detail on 1/19/22 with an annotated graph under the headline, "Stalled and Slumped Well Below 50 DMA Line". It was dropped from the Featured Stocks list on 1/24/22 yet found support near its 200 DMA line then rebounded and rose to new highs.
The number of top-rated funds owning its shares rose from 3,055 in Dec '20 to 3,554 in Mar '22, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.2 is an unbiased indication its shares have been under slight accumulation over the past 50 days. It has a Timeliness Rating of A and a Sponsorship Rating of B. There are 952.3 million shares outstanding, making it an unlikely sprinter, while it is also well-recognized already by the institutional crowd.
Stalled and Slumped Well Below 50 DMA Line - Wednesday, January 19, 2022
Eli Lilly & Co (LLY -$2.02 or -0.82% to $245.05) has not rebounded after slumping well below its 50-day moving average (DMA) line ($259.50) with recent volume-driven losses raising concerns and triggering a technical sell signal. A rebound above the 50 DMA line is needed for its outlook to improve.
This giant Medical - Diversified firm has stalled and faltered after briefly rising from a choppy 17-week consolidation. LLY was highlighted in yellow in the 12/16/21 mid-day report (read here) with pivot point cited based on its 8/17/21 high plus 10 cents. It was covered in greater detail that evening with an annotated graph under the headline, "Eli Lilly & Co Powered to New Highs With Volume".
LLY has an Earnings Per Share Rating of 93. It reported Sep '21 quarterly earnings +38% on +18% sales revenues versus the year ago period, and 3 of the past 4 quarterly comparisons were above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) improved steadily since a downturn in FY '14.
The number of top-rated funds owning its shares rose from 3,055 in Dec '20 to 3,367 in Dec '21, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 0.7 is an unbiased indication its shares have been under distributional pressure over the past 50 days. It has a Timeliness Rating of C and a Sponsorship Rating of B. There are 956.6 million shares outstanding, making it an unlikely sprinter, while it is also well-recognized already by the institutional crowd.
Eli Lilly & Co Powered to New Highs With Volume - Thursday, December 16, 2021
Eli Lilly & Co (LLY +$3.76 or +1.37% to $279.04) was highlighted in yellow in the earlier mid-day report (read here) with pivot point cited based on its 8/17/21 high plus 10 cents. It clinched a technical buy signal as volume was +78% above average as this giant Medical - Diversified firm powered to new all-time highs with today's 5th consecutive gain after a choppy 17-week consolidation.
LLY has an Earnings Per Share Rating of 93. It reported Sep '21 quarterly earnings +38% on +18% sales revenues versus the year ago period, and 3 of the past 4 quarterly comparisons were above the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) improved steadily since a downturn in FY '14.
The number of top-rated funds owning its shares rose from 3,055 in Dec '20 to 3,372 in Sep '21, a reassuring sign concerning the I criteria. Its current Up/Down Volume Ratio of 1.4 is an unbiased indication its shares have been under accumulation over the past 50 days. It has a Timeliness Rating of B and a Sponsorship Rating of B. However, there are 956.6 million shares outstanding, making it an unlikely sprinter, while it is also well-recognized already by the institutional crowd.
